| US 7,429,667 B2 | ||
| Phenylamino isothiazole carboxamidines as MEK inhibitors | ||
| Hassan Abdellaoui, Aliso Viejo, Calif. (US); Robert Tam, Irvine, Calif. (US); Huanming Chen, Irvine, Calif. (US); Varaprasad Chamakura, Irvine, Calif. (US); Dinesh Barawkar, Foothill Ranch, Calif. (US); Andreas Maderna, Los Angeles, Calif. (US); Zhi Hong, Irvine, Calif. (US); and Stanley Lang, Laguna Niguel, Calif. (US) | ||
| Assigned to Ardea Biosciences, Inc., San Diego, Calif. (US) | ||
| Filed on Jan. 20, 2006, as Appl. No. 11/337,243. | ||
| Claims priority of provisional application 60/691698, filed on Jun. 16, 2005. | ||
| Claims priority of provisional application 60/688628, filed on Jun. 07, 2005. | ||
| Claims priority of provisional application 60/688006, filed on Jun. 06, 2005. | ||
| Claims priority of provisional application 60/688005, filed on Jun. 06, 2005. | ||
| Claims priority of provisional application 60/685194, filed on May 26, 2005. | ||
| Claims priority of provisional application 60/685131, filed on May 26, 2005. | ||
| Claims priority of provisional application 60/675397, filed on Apr. 27, 2005. | ||
| Claims priority of provisional application 60/653340, filed on Feb. 16, 2005. | ||
| Claims priority of provisional application 60/645425, filed on Jan. 20, 2005. | ||
| Prior Publication US 2006/0194802 A1, Aug. 31, 2006 | ||
| Int. Cl. C07D 275/03 (2006.01); C07D 413/12 (2006.01); C07D 239/36 (2006.01); C07D 217/06 (2006.01); C07D 401/12 (2006.01); C07D 401/14 (2006.01); C07D 417/12 (2006.01) | ||
| U.S. Cl. 548—213 [544/145; 544/298; 544/367; 546/145; 546/171; 546/209; 546/256; 546/271.1] | 13 Claims |
1. A compound of formula I
![]() where Ar1 is phenyl, pyridyl, pyrimidyl, pyridazinyl, or triazinyl, in which all ring carbon atoms are optionally substituted with substituents
R1, R2, and R3, which are selected independently from hydrogen; halogen; hydroxy; nitro; cyano; C1-C4 alkyl, optionally substituted with one to three fluorine atoms; CH3O; 2-methoxy ethenyl; (CH3)2N; CH3OC(O); CH3CH2OC(O); NR7R8, —C(O)NR7R8; or —S(O)2NR7R8, where R7 and R8 are, independently, H, CH3, or CH3CH2; and R1 may also be 2-C(O)K, where K is selected from:
—OJ, where J is isopropyl, cyclopropyl, cyclopentyl, dimethylamino, or methoxyethyl;
—NHJ′ where J′ is methyl, ethyl, isopropyl, cyclopropyl, dimethylaminomethyl, or 3-methyl-2-yl-butanoic acid methyl ester;
and
—N(CH3)2; or 4-methylpiperzin-1-yl;
or R1 and R2 are attached to adjacent carbons and, together with the ring atoms to which they are attached, form an additional, fused,
five- or six-membered ring, optionally containing one heteroatom, which ring may be aromatic or aliphatic;
A is O, S, CH2, N2, CO, NHCO, COCH2, or CH2CO;
or Ar1-A is
![]() where the five-membered ring is fused to Ar1 and Y is NH, S, or O;
or Ar1-A is
![]() where the dotted line represents an optional double bond, the five-membered ring is fused to Ar1, and Rx is selected from substituents listed above for R3;
or Ar1-A is
![]() where the five-membered ring is fused to Ar1, and Rx is selected from substituents listed above for R3;
Ar2 is phenyl, pyridyl, pyrimidyl, pyridazinyl, or triazinyl, where ring carbon atoms are optionally substituted with substituents
R4-R6 which are selected independently from H, F, Cl, Br, CH3, or CF3;
or Ar2—NH— is
![]() where Ry is selected from substituents listed above for R3;
and R′ is OH; O—C1-C6 alkyl; C1-C6 alkyl, said C1-C6 alkyl groups optionally substituted with one to three groups selected independently from hydroxy, halogen, C1-C3 alkoxy, and phenyl; —CH2B or —CH2CH2B, where B is selected from C3-7 cycloalkyl, C7-C9 bicycloalkyl, pyridyl, piperazinyl, piperidinyl, N-morpholyl, tetrahydrofuryl, and naphthyl; C3-C7 cycloalkyl; C7-C9 bicycloalkyl, where all cycloalkyl, bicycloalkyl, pyridyl, piperazinyl, piperidinyl, N-morpholyl, tetrahydrofuryl, and naphthyl
groups are optionally substituted with one to three groups selected independently from hydroxy, halogen, and methyl;
or R′ is (CH2)n-G, where n is 1 or 2 and G is a five- or six-membered ring or a 9-14-membered fused ring system, wherein each ring optionally
contains 1-3 heteroatoms selected independently from O, N, and S; wherein each ring is optionally substituted with 1-3 groups
selected independently from the following: halogen, hydroxy, cyano, oxo, and C1-C4 alkyl, wherein said C1-C4 alkyl group is optionally substituted with one to three halogen atoms; and wherein each ring optionally contains one or more
double bonds;
or R′ is —CH(CH2OH)CH2D, where D is selected from imidazolyl, indolyl, carboxamido, phenyl, cyclohexyl, —CH2SCH3, and adamantin-1-yl.
|